替米沙坦联合依那普利对2型糖尿病早期肾病的临床观察

目的观察替米沙坦和依那普利联用治疗2型糖尿痛早期肾病的疗效。方法108例合并糖尿病早期肾病的2型糖尿病患者，随机均分为3组：替米沙坦组（80mg／天），依那普利组（10mg/天），联合治疗组即替米沙坦联合依那普利组（替米沙坦80mg／天＋依那普利10mg／天），3组均使用常规药物治疗。各组治疗4月后，检测尿微量白蛋白排泄率、血压、血肌酐、尿素氮、空腹血糖、血钾水平。结果3组治疗后尿微量白蛋白排泄率、血压均有下降，且联用组较单用组下降更显著，而血糖、血肌酐、尿素氮、血钾无明显变化。结论对于2型糖尿病早期肾病患者，替米沙坦联合依那普利比单药使用更能有效降低尿微量白蛋白，延缓糖尿病早期肾病的发展。

The Clinical Observation of Telmisartan Combined Enalapril on Type 2 Diabetes Early Nephropathy

Objective To observe the effect of Telmlsartan combined Enalapril on early diabetic nephropathy in type 2 diabetes. Method 108 type 2 diabeteic patients with early diabetic nephropathy were randomly divided into three groups： Telmisartan（ 80 mg/d）, Enalapril （10 mg/d） and combination group （Telmisartan 80 mg/d ＋ Enalapril 10 mg/d）, all of the patients in three groups were treated with routilae drugs. After four mouths, their UAER, blood pressure, Scr, BUN, FPG, and potassium were measured. Result 24 hours UAER and blood pressure decreased in three groups,and those in combination group were significantly lower than Telmisartan group and Enalapril group, but Scr, BUN, FPG, and potassium did not change notably. Conclusion Combination of Telmisartan and Enalapril can significantly decrease the UAER compared with the agents used separately in type 2 diabeteic patients with early diabetic nephropathyand delay progress of the disease.